The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Managing Immune Checkpoint-Blocking Antibody Side Effects
Open accessAbstract
Immune checkpoint-blocking antibodies that enhance the immune system's ability to fight cancer are becoming important components of treatment for patients with a variety of malignancies. Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) was the first immune checkpoint to be clinically targeted, and ipilimumab, an inhibitor of CTLA-4, was approved by the U.S. Food and Drug Administration (FDA) for patients with advanced melanoma. The programmed cell death-1 (PD-1) receptor and one of its ligands, PD-L1, more recently have shown great promise as therapeutic targets in a variety of malignancies. Nivolumab and pembrolizumab recently have been FDA- approved for patients with melanoma and additional approvals within this therapeutic class are expected. The use of anti-CTLA-4 and anti-PD-1/PD-L1 antibodies is associated with side effects known as immune-related adverse events (irAEs). Immune-related adverse events affect the dermatologic, gastrointestinal, hepatic, endocrine, and other organ systems. Temporary immunosuppression with corticosteroids, tumor necrosis factor-alpha antagonists, mycophenolate mofetil, or other agents can be effective treatment. This article describes the side-effect profile of the checkpoint-blocking antibodies that target CTLA-4 and PD-1/PD-L1 and provides suggestions on how to manage specific irAEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citationPD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Self-citationManagement of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0703 · Cited by 1,074
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
Ribas, A., Kefford, R., Marshall, M. A., Punt, C. J. A., Haanen, J. B., Marmol, M., Garbe, C., Gogas, H., Schachter, J., Linette, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.6112 · Cited by 805
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742
Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Ribas, A., Hodi, F. S., Callahan, M., Konto, C., & Wolchok, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302338 · Cited by 714
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051848 · Cited by 698
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Weber, J., Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I., Ridolfi, R., Assi, H., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 568
Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535
Voskens, C. J., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 468
Weber, J. S., Dummer, R., de Pril, V., Lebbé, C., Hodi, F. S., & for the MDX010‐20 Investigators (2013) · Cancer · doi:10.1002/cncr.27969 · Cited by 447
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439
Self-citationEndocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
Hodi, F. S., Lee, S., McDermott, D. F., Rao, U. N., Butterfield, L. H., Tarhini, A. A., Leming, P., Puzanov, I., Shin, D., & Kirkwood, J. M. (2014) · JAMA · doi:10.1001/jama.2014.13943 · Cited by 359
Blansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 355
Anti-CTLA4 Antibody–Induced Lupus Nephritis
Fadel, F., Karoui, K. E., & Knebelmann, B. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904283 · Cited by 300
Dillard, T., Yedinak, C. G., Alumkal, J., & Fleseriu, M. (2010) · Pituitary · doi:10.1007/s11102-009-0193-z · Cited by 300
Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes
Lühder, F., Höglund, P., Allison, J. P., Benoist, C., & Mathis, D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.3.427 · Cited by 290
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
Liao, B., Shroff, S., Kamiya-Matsuoka, C., & Tummala, S. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou001 · Cited by 288
Di Giacomo, A. M., Danielli, R., Guidoboni, M., Calabrò, L., Carlucci, D., Miracco, C., Volterrani, L., Mazzei, M. A., Biagioli, M., Altomonte, M., et al. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0642-y · Cited by 286
Ipilimumab associated hepatitis: imaging and clinicopathologic findings
Kim, K. W., Ramaiya, N. H., Krajewski, K. M., Jagannathan, J. P., Tirumani, S. H., Srivastava, A., & Ibrahim, N. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9939-6 · Cited by 235
Johnson, D. B., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Kefford, R. F., Hamid, O., Schuchter, L., Cebon, J., Sharfman, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3535 · Cited by 216
Sarnaik, A. A., Yu, B., Yu, D., Morelli, D., Hall, M., Bogle, D., Yan, L., Targan, S., Solomon, J., Nichol, G., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2463 · Cited by 202
Stidham, R. W., Lee, T. C. H., Higgins, P. D. R., Deshpande, A. R., Sussman, D. A., Singal, A. G., Elmunzer, B. J., Saini, S. D., Vijan, S., & Waljee, A. K. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12749 · Cited by 201
Ipilimumab in patients with cancer and the management of dermatologic adverse events
Lacouture, M. E., Wolchok, J. D., Yosipovitch, G., Kähler, K. C., Busam, K. J., & Hauschild, A. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.02.035 · Cited by 187
Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
Berthod, G., Lazor, R., Letovanec, I., Romano, E., Noirez, L., Mazza Stalder, J., Speiser, D. E., Peters, S., & Michielin, O. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3298 · Cited by 182
Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patient
Wilgenhof, S., & Neyns, B. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr028 · Cited by 175
Kidney injuries related to ipilimumab
Izzedine, H., Gueutin, V., Gharbi, C., Mateus, C., Robert, C., Routier, E., Thomas, M., Baumelou, A., & Rouvier, P. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0092-7 · Cited by 171
Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
Chmiel, K. D., Suan, D., Liddle, C., Nankivell, B., Ibrahim, R., Bautista, C., Thompson, J., Fulcher, D., & Kefford, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2206 · Cited by 164
Robinson, M. R., Chan, C.-C., Yang, J. C., Rubin, B. I., Gracia, G. J., Sen, H. N., Csaky, K. G., & Rosenberg, S. A. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00008 · Cited by 159
Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
Sapkota, B., Hill, C. E., & Pollack, B. P. (2013) · OncoImmunology · doi:10.4161/onci.22890 · Cited by 158
Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
Kleiner, D. E., & Berman, D. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2140-5 · Cited by 148
Comín-Anduix, B., Chodon, T., Sazegar, H., Matsunaga, D. R., Mock, S., Jalil, J., Escuin-Ordinas, H., Chmielowski, B., Koya, R. C., & Ribas, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1911 · Cited by 143
Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
Eckert, A., Schoeffler, A., Dalle, S., Phan, A., Kiakouama, L., & Thomas, L. (2008) · Dermatology · doi:10.1159/000161122 · Cited by 138
Neurological immune-related adverse events of ipilimumab
Bot, I., Blank, C. U., Boogerd, W. J., & Brandsma, D. (2013) · Practical Neurology · doi:10.1136/practneurol-2012-000447 · Cited by 137
Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma
Maur, M., Tomasello, C., Frassoldati, A., Dieci, M. V., Barbieri, E., & Conte, P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7886 · Cited by 134
Ipilimumab-induced acute severe colitis treated by infliximab
Pagès, C., Gornet, J. M., Monsel, G., Allez, M., Bertheau, P., Bagot, M., Lebbé, C., & Viguier, M. A. (2013) · Melanoma Research · doi:10.1097/cmr.0b013e32835fb524 · Cited by 129
Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
Callahan, M. K., Masters, G. R., Pratilas, C. A., Ariyan, C. E., Katz, J. B., Kitano, S., Russell, V., Gordon, R. A., Vyas, S., Yuan, J. D., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0160 · Cited by 121
Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
Minor, D. R., Chin, K., & Kashani-Sabet, M. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0607 · Cited by 120
Opportunistic infections in patients treated with immunotherapy for cancer
Kyi, C., Hellmann, M. D., Wolchok, J. D., Chapman, P. B., & Postow, M. A. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-19 · Cited by 120
Self-citationOrganizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
Barjaktarević, I., Qadir, N., Suri, A., Santamauro, J. T., & Stover, D. E. (2013) · CHEST Journal · doi:10.1378/chest.12-1467 · Cited by 116
Hemophilia A Induced by Ipilimumab
Delyon, J., Mateus, C., & Lambert, T. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1110923 · Cited by 106
Bhatia, S., Huber, B. R., Upton, M. P., & Thompson, J. A. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318193a206 · Cited by 104
Min, L., & Hodi, F. S. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0146 · Cited by 101
Vemurafenib Sensitivity Skin Reaction after Ipilimumab
Harding, J. J., Pulitzer, M. P., & Chapman, P. B. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1114329 · Cited by 94
Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)
Akhtari, M., Waller, E. K., Jaye, D. L., Lawson, D. H., Ibrahim, R. A., Papadopoulos, N., & Arellano, M. L. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819aa40b · Cited by 94
Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
Gettings, E. J., Hackett, C., & Scott, T. F. M. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514549403 · Cited by 93
Ipilimumab in patients with melanoma and autoimmune disease
Kyi, C., Carvajal, R. D., Wolchok, J. D., & Postow, M. A. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0035-z · Cited by 90
Self-citationSweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy
Pintova, S., Sidhu, H. K., Friedlander, P. A., et al. (2013) · Melanoma Research · doi:10.1097/cmr.0000000000000017 · Cited by 82
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
Gordon, I. O., Wade, T., Chin, K. M., Dickstein, J. I., & Gajewski, T. F. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0627-x · Cited by 81
Eggermont, A. M. M., Chiarion‐Sileni, V., Grob, J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.18_suppl.lba9008 · Cited by 77
Anti-CTLA-4 Antibody Treatment Triggers Determinant Spreading and Enhances Murine Myasthenia Gravis
Wang, H., Shi, F., Li, H., Chambers, B. J., Link, H., & Ljunggren, H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.10.6430 · Cited by 76
Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5009 · Cited by 72
Merrill, S. P., Reynolds, P., Kalra, A., Biehl, J., Vandivier, R. W., & Mueller, S. W. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014528152 · Cited by 68
Ipilimumab-induced immune-related renal failure--a case report.
Forde, P. M., Rock, K., Wilson, G. F., & O'Byrne, K. J. (2012) · Anticancer Research · Cited by 64
Defective Leukocyte GM-CSF Receptor (CD116) Expression and Function in Inflammatory Bowel Disease
Goldstein, J. I., Kominsky, D. J., Jacobson, N. E., Bowers, B., Regalia, K. A., Austin, G. L., Yousefi, M., Falta, M. T., Fontenot, A. P., Gerich, M. E., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.060 · Cited by 63
Pedersen, M., Andersen, R. S., Nørgaard, P. H., Jacobsen, S., Thielsen, P., Straten, P. T., & Svane, I. M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1607-y · Cited by 58
Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
Bernardo, S. G., Москаленко, М., Pan, M. M., Shah, S. D., Sidhu, H. K., Sicular, S., Harcharik, S., Chang, R. R., Friedlander, P. A., & Saenger, Y. M. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e32835c7e68 · Cited by 55
Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review
Kopecký, J., Trojanova, P., ek, O. K., & Kopecký, O. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu222 · Cited by 33
Cited by
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
“Where the patient’s condition does not improve or there is no imaging improvement after 2 days, additional immunosuppressive strategies should be implemented [55, 70, 71].”
BackgroundToxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Self-citationImmune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
Metadata
- Authors
- Postow, M. A.
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2015-05
- Issue
- 35
- Pages
- 76-83
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W1605630196
- Cited by
- 403
- References
- 81
- FWCI
- 22.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.